Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy

World Journal of Gastroenterology

Volumn 18, Issue 47, 2012, Pages 7026-7032

  Ang, Jian ^a   Hu, Liang ^a   Huang, Pin Tong ^a   Wu, Jin Xiu ^a   Huang, Ling Na ^a   Cao, Chun Hui ^a   Zheng, Yi Xiong ^a   Chen, Li ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemotherapy; Disease management; Gastric cancer; Predictive value of tests; Ultrasonic imaging

Indexed keywords

FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IOHEXOL; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG RESPONSE; ECHOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLE CYCLE TREATMENT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TREATMENT RESPONSE; TUMOR VASCULARIZATION; YOUDEN INDEX;

EID: 84873884822     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i47.7026     Document Type: Article

References (26)

1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
2. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009; 22: 1555-1563
3. Afaq A, Akin O. Imaging assessment of tumor response: past, present and future. Future Oncol 2011; 7: 669-677
4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
5. Huang P, Li S, Aronow WS, Wang Z, Nair CK, Xue N, Shen X, Chen C, Cosgrove D. Double contrast-enhanced ultrasonography evaluation of preoperative Lauren classification of advanced gastric carcinoma. Arch Med Sci 2011; 7: 287-293
6. Zheng Z, Yu Y, Lu M, Sun W, Wang F, Li P, Zhang Y, Lin L, Huang P, Chen J, Zhang H, Xie Z, Dong Xda E. Double contrast-enhanced ultrasonography for the preoperative evaluation of gastric cancer: a comparison to endoscopic ultrasonography with respect to histopathology. Am J Surg 2011; 202: 605-611
7. Mandard AM, Dalibard F, Mandard JC, Marnay J, HenryAmar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686
8. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308
9. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218
10. Fushida S, Nashimoto A, Fukushima N, Kawachi Y, Fujimura T, Kuwabara S, Musha N. Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer. Jpn J Clin Oncol 2012; 42: 131-133
11. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR. A phase II study of biweekly oxaliplatin plus infusional 5-fuorouracil and folinic acid (FOLFOX-4) as frst-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644-1649
12. Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, Wu Q, Zong XL, Ren H, Tang L, Zhang XP, Li JY, Hu Y, Shen L, Ji JF. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol 2012; 105: 793-799
13. Guerra L, Niespolo R, Di Pisa G, Ippolito D, De Ponti E, Terrevazzi S, Bovo G, Sironi S, Gardani G, Messa C. Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdom Imaging 2011; 36: 38-45
14. Mallery S, DeCamp M, Bueno R, Mentzer SJ, Sugarbaker DJ, Swanson SJ, Van Dam J. Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma. Cancer 1999; 86: 764-769
15. Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 2004; 91: 199-204
16. Wang LB, Teng RY, Jiang ZN, Hu WX, Dong MJ, Yuan XM, Chen WJ, Jin M, Shen JG. Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. J Surg Oncol 2012; 105: 293-296
17. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009; 72: 217-238
18. Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophagogastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer 2011; 11: 266
19. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97: 172-187
20. Zhou JH, Cao LH, Zheng W, Liu M, Han F, Li AH. Contrastenhanced gray-scale ultrasound for quantitative evaluation of tumor response to chemotherapy: preliminary results with a mouse hepatoma model. AJR Am J Roentgenol 2011; 196: W13-W17
21. Kanamori A, Hirooka Y, Itoh A, Hashimoto S, Kawashima H, Hara K, Uchida H, Goto J, Ohmiya N, Niwa Y, Goto H. Usefulness of contrast-enhanced endoscopic ultrasonography in the differentiation between malignant and benign lymphadenopathy. Am J Gastroenterol 2006; 101: 45-51
22. McCarville MB, Streck CJ, Dickson PV, Li CS, Nathwani AC, Davidoff AM. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 2006; 240: 73-81
23. Lavisse S, Lejeune P, Rouffac V, Elie N, Bribes E, Demers B, Vrignaud P, Bissery MC, Brulé A, Koscielny S, Péronneau P, Lassau N. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008; 43: 100-111
24. Broillet A, Hantson J, Ruegg C, Messager T, Schneider M. Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. Acad Radiol 2005; 12 Suppl 1: S28-S33
25. Bertolotto M, Pozzato G, Crocè LS, Nascimben F, Gasparini C, Cova MA, Tiribelli C. Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. Invest Radiol 2006; 41: 15-21
26. Schirin-Sokhan R, Winograd R, Roderburg C, Bubenzer J, do Ó NC, Guggenberger D, Hecker H, Trautwein C, Tischendorf JJ. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol 2012; 18: 541-545